{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:14:12Z","timestamp":1795025652341,"version":"4.10.2"},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>Standard-of-care biomarkers for renal allograft rejection are lagging indicators, signaling existing organ injury. This precludes early intervention, when immunological cascades leading to rejection are most susceptible. Donor-derived cell-free DNA (dd-cfDNA) shows promise as an early indicator of rejection, allowing earlier and possibly more effective treatment. This analysis was designed to assess this promise using real-world dd-cfDNA testing evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>This retrospective analysis of the prospective, observational ProActive registry study (NCT04091984) assessed dd-cfDNA and serum creatinine levels before biopsy in 424 patients with \u22651 dd-cfDNA test (n\u2005=\u20051013) in the 6 mo before biopsy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>Of 4667 enrolled patients, 1631 patients had \u226518 mo of follow-up data, of which 424 had a biopsy and were included in this analysis. Twenty-six biopsies showed antibody-mediated rejection (ABMR), 62 showed T cell\u2013mediated rejection, and 336 showed nonrejection; each from a unique patient. dd-cfDNA fractions were significantly elevated 5 mo before ABMR biopsies, and 2 mo before T cell\u2013mediated rejection biopsies, compared with nonrejection biopsies. In contrast, serum creatinine did not discriminate between rejection and nonrejection in advance, or concurrent with biopsy. Among patients with nonrejection biopsies, estimated glomerular filtration rate was significantly lower in cases with \u22652 increased dd-cfDNA results (\u22651%), compared with those with 0 or 1 increased dd-cfDNA result.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>These data indicate that dd-cfDNA is an early indicator of biopsy-proven rejection, especially ABMR, suggesting a greater role for dd-cfDNA in surveillance to identify patients at high risk of ongoing or future rejection, thus requiring closer monitoring, biopsy, or other management changes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/tp.0000000000005007","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T04:12:09Z","timestamp":1712722329000},"page":"1994-2004","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":59,"title":["Elevation of Donor-derived Cell-free DNA Before Biopsy-proven Rejection in Kidney Transplant"],"prefix":"10.1097","volume":"108","author":[{"given":"Jonathan S.","family":"Bromberg","sequence":"first","affiliation":[{"name":"Department of Surgery, University of Maryland, School of Medicine, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suphamai","family":"Bunnapradist","sequence":"additional","affiliation":[{"name":"UCLA School of Medicine, Los Angeles, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milagros","family":"Samaniego-Picota","sequence":"additional","affiliation":[{"name":"Henry Ford Transplant Institute, Detroit, MI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv","family":"Anand","sequence":"additional","affiliation":[{"name":"Intermountain Healthcare, Salt Lake City, UT."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Stites","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Colorado Anschutz Medical Campus, Denver, CO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gauthier","sequence":"additional","affiliation":[{"name":"Natera, Inc., Austin, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Demko","sequence":"additional","affiliation":[{"name":"Natera, Inc., Austin, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Prewett","sequence":"additional","affiliation":[{"name":"Natera, Inc., Austin, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Armer-Cabral","sequence":"additional","affiliation":[{"name":"Natera, Inc., Austin, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Marshall","sequence":"additional","affiliation":[{"name":"Natera, Inc., Austin, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navchetan","family":"Kaur","sequence":"additional","affiliation":[{"name":"Natera, Inc., Austin, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle S.","family":"Bloom","sequence":"additional","affiliation":[{"name":"Natera, Inc., Austin, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Tabriziani","sequence":"additional","affiliation":[{"name":"Natera, Inc., Austin, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Bhorade","sequence":"additional","affiliation":[{"name":"Natera, Inc., Austin, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Cooper","sequence":"additional","affiliation":[{"name":"Department of Surgery, Medical College of Wisconsin, Milwaukee, WI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the ProActive Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,8,20]]},"reference":[{"key":"R1-20250604","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.2174\/1381612826666200610184433","article-title":"Acute rejection following kidney transplantation: state-of-the-art and future perspectives.","volume":"26","author":"Rodrigo","year":"2020","journal-title":"Curr Pharm Des"},{"key":"R2-20250604","doi-asserted-by":"crossref","first-page":"661643","DOI":"10.3389\/fimmu.2021.661643","article-title":"Tackling chronic kidney transplant rejection: challenges and promises.","volume":"12","author":"Lai","year":"2021","journal-title":"Front Immunol"},{"key":"R3-20250604","doi-asserted-by":"crossref","first-page":"1031894","DOI":"10.3389\/fgene.2022.1031894","article-title":"Donor-derived cell-free DNA as a diagnostic tool in transplantation.","volume":"13","author":"Oellerich","year":"2022","journal-title":"Front Genet"},{"key":"R4-20250604","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1111\/ajt.15898","article-title":"The Banff 2019 Kidney Meeting Report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection.","volume":"20","author":"Loupy","year":"2020","journal-title":"Am J Transplant"},{"issue":"Suppl 4","key":"R5-20250604","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/ajt.15844","article-title":"Mechanisms of organ transplant injury mediated by B cells and antibodies: implications for antibody-mediated rejection.","volume":"20","author":"Chong","year":"2020","journal-title":"Am J Transplant"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41581-021-00428-0","article-title":"Liquid biopsies: donor-derived cell-free DNA for the detection of kidney allograft injury.","volume":"17","author":"Oellerich","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"R7-20250604","first-page":"63","article-title":"Acute kidney injury biomarkers\u2014needs, present status, and future promise.","volume":"5","author":"Zhou","year":"2006","journal-title":"Nephrol Self Assess Program"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1681\/ASN.2005030285","article-title":"American Society of Nephrology Renal Research Report.","volume":"16","author":"American Society of","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R9-20250604","doi-asserted-by":"crossref","first-page":"11321","DOI":"10.3389\/ti.2023.11321","article-title":"The clinical utility of post-transplant monitoring of donor-specific antibodies in stable renal transplant recipients: a consensus report with guideline statements for clinical practice.","volume":"36","author":"van den Broek","year":"2023","journal-title":"Transpl Int"},{"key":"R10-20250604","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1097\/TP.0000000000004212","article-title":"Combining donor-derived cell-free DNA fraction and quantity to detect kidney transplant rejection using molecular diagnoses and histology as confirmation.","volume":"106","author":"Halloran","year":"2022","journal-title":"Transplantation"},{"key":"R11-20250604","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/TP.0000000000004324","article-title":"Antibody-mediated rejection without detectable donor-specific antibody releases donor-derived cell-free DNA: results from the Trifecta study.","volume":"107","author":"Halloran","year":"2023","journal-title":"Transplantation"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1055\/s-2004-861562","article-title":"Biopsy of the transplanted kidney.","volume":"21","author":"Ahmad","year":"2004","journal-title":"Semin Intervent Radiol"},{"key":"R13-20250604","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/jorc.12161","article-title":"How do patients experience a kidney biopsy?","volume":"42","author":"Finderup","year":"2016","journal-title":"J Ren Care"},{"key":"R14-20250604","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1111\/ajt.15416","article-title":"Absolute quantification of donor-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation: results from a prospective observational study.","volume":"19","author":"Oellerich","year":"2019","journal-title":"Am J Transplant"},{"key":"R15-20250604","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/TP.0000000000002482","article-title":"Donor-specific cell-free DNA as a biomarker in solid organ transplantation. A systematic review.","volume":"103","author":"Knight","year":"2019","journal-title":"Transplantation"},{"key":"R16-20250604","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1681\/ASN.2016091034","article-title":"Cell-free DNA and active rejection in kidney allografts.","volume":"28","author":"Bloom","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"R17-20250604","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/jcm8010019","article-title":"Optimizing detection of kidney transplant injury by assessment of donor-derived cell-free DNA via massively multiplex PCR.","volume":"8","author":"Sigdel","year":"2018","journal-title":"J Clin Med"},{"key":"R18-20250604","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.healun.2022.04.002","article-title":"A novel donor-derived cell-free DNA assay for the detection of acute rejection in heart transplantation.","volume":"41","author":"Kim","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"R19-20250604","doi-asserted-by":"crossref","first-page":"e1317","DOI":"10.1097\/TXD.0000000000001317","article-title":"Clinical validation of a plasma donor-derived cell-free DNA assay to detect allograft rejection and injury in lung transplant.","volume":"8","author":"Rosenheck","year":"2022","journal-title":"Transplant Direct"},{"key":"R20-20250604","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ebiom.2018.12.029","article-title":"Donor-derived cell-free DNA predicts allograft failure and mortality after lung transplantation.","volume":"40","author":"Agbor-Enoh","year":"2019","journal-title":"EBioMedicine"},{"key":"R21-20250604","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/TP.0000000000004267","article-title":"An assessment of the value of donor-derived cell-free DNA surveillance in patients with preserved kidney allograft function.","volume":"107","author":"Huang","year":"2023","journal-title":"Transplantation"},{"key":"R22-20250604","doi-asserted-by":"crossref","first-page":"241ra277","DOI":"10.1126\/scitranslmed.3007803","article-title":"Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection.","volume":"6","author":"De Vlaminck","year":"2014","journal-title":"Sci Transl Med"},{"key":"R23-20250604","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1097\/TP.0000000000004877","article-title":"Distinct molecular processes mediate donor-derived cell-free DNA release from kidney transplants in different disease states.","volume":"108","author":"Gauthier","year":"2024","journal-title":"Transplantation"},{"key":"R24-20250604","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/14728214.2022.2091131","article-title":"Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials.","volume":"27","author":"Mayer","year":"2022","journal-title":"Expert Opin Emerg Drugs"},{"key":"R25-20250604","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.2215\/CJN.03320708","article-title":"The declaration of Istanbul on organ trafficking and transplant tourism.","volume":"3","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R26-20250604","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race.","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"R27-20250604","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1097\/TP.0000000000002665","article-title":"Analytical validation of a single-nucleotide polymorphism-based donor-derived cell-free DNA assay for detecting rejection in kidney transplant patients.","volume":"103","author":"Altug","year":"2019","journal-title":"Transplantation"},{"key":"R28-20250604","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing.","volume":"57","author":"Benjamini","year":"1995","journal-title":"J Royal Stat Soc"},{"key":"R29-20250604","first-page":"881","article-title":"Robust statistical modeling using the t distribution.","volume":"84","author":"Lange","year":"1989","journal-title":"J Am Stat Assoc"},{"key":"R30-20250604","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/biomet\/asq017","article-title":"The horseshoe estimator for sparse signals.","volume":"97","author":"Carvalho","year":"2010","journal-title":"Biometrika"},{"key":"R31-20250604","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1007\/s11222-016-9709-3","article-title":"Practical Bayesian model evaluation using leave-one-out cross-validation and WAIC.","volume":"27","author":"Vehtari","year":"2016","journal-title":"Stat Comput"},{"key":"R32-20250604","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v080.i01","article-title":"brms: An R package for Bayesian multilevel models using Stan.","volume":"80","author":"B\u00fcrkner","year":"2017","journal-title":"J Stat Software"},{"key":"R34-20250604","first-page":"1354","article-title":"A package for retrospective cohort matching in Python.","volume":"2022","author":"Kline","year":"2022","journal-title":"Annu Int Conf IEEE Eng Med Biol Soc"},{"issue":"2 Suppl 1","key":"R35-20250604","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.ajt.2023.02.004","article-title":"OPTN\/SRTR 2021 annual data report: kidney.","volume":"23","author":"Lentine","year":"2023","journal-title":"Am J Transplant"},{"key":"R36-20250604","doi-asserted-by":"crossref","first-page":"761919","DOI":"10.3389\/fmed.2021.761919","article-title":"Influence of persistent inflammation in follow-up biopsies after antibody-mediated rejection in kidney transplantation.","volume":"8","author":"Pineiro","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R37-20250604","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1056\/NEJMoa020009","article-title":"The natural history of chronic allograft nephropathy.","volume":"349","author":"Nankivell","year":"2003","journal-title":"N Engl J Med"},{"key":"R38-20250604","first-page":"2580","article-title":"Antibody-mediated rejection of solid-organ allografts.","volume":"379","author":"Lefaucheur","year":"2018","journal-title":"N Engl J Med"},{"key":"R39-20250604","doi-asserted-by":"crossref","first-page":"a015461","DOI":"10.1101\/cshperspect.a015461","article-title":"Effector mechanisms of rejection.","volume":"3","author":"Moreau","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"key":"R40-20250604","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1146\/annurev.pathmechdis.3.121806.151508","article-title":"Kidney transplantation: mechanisms of rejection and acceptance.","volume":"3","author":"Cornell","year":"2008","journal-title":"Annu Rev Pathol"},{"key":"R41-20250604","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nri3215","article-title":"The impact of infection and tissue damage in solid-organ transplantation.","volume":"12","author":"Chong","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"R42-20250604","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.ajpath.2022.04.003","article-title":"Molecular signature of antibody-mediated chronic vasculopathy in heart allografts in a novel mouse model.","volume":"192","author":"Tsuda","year":"2022","journal-title":"Am J Pathol"},{"key":"R43-20250604","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.kint.2020.03.037","article-title":"Early T cell infiltration is modulated by programed cell death-1 protein and its ligand (PD-1\/PD-L1) interactions in murine kidney transplants.","volume":"98","author":"Shim","year":"2020","journal-title":"Kidney Int"},{"key":"R44-20250604","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/TP.0000000000004377","article-title":"Beyond adaptive alloreactivity: contribution of innate B cells to allograft inflammation and rejection.","volume":"107","author":"Sayin","year":"2023","journal-title":"Transplantation"},{"key":"R45-20250604","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/TP.0000000000004647","article-title":"The entangled world of memory T cells and implications in transplantation.","volume":"108","author":"Alexander","year":"2024","journal-title":"Transplantation"},{"key":"R46-20250604","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1681\/ASN.2021040433","article-title":"Donor-specific antibody is associated with increased expression of rejection transcripts in renal transplant biopsies classified as no rejection.","volume":"32","author":"Madill-Thornsen","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"R47-20250604","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1681\/ASN.2021040433","article-title":"Donor-specific antibody is associated with increased expression of rejection transcripts in renal transplant biopsies classified as no rejection.","volume":"32","author":"Madill-Thomsen","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"R48-20250604","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1681\/ASN.2020101418","article-title":"Data-driven derivation and validation of novel phenotypes for acute kidney transplant rejection using semi-supervised clustering.","volume":"32","author":"Vaulet","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"R49-20250604","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/TP.0000000000004624","article-title":"The molecular phenotype of kidney transplants: insights from the MMDx project.","volume":"108","author":"Halloran","year":"2024","journal-title":"Transplantation"},{"key":"R50-20250604","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1097\/TP.0000000000002566","article-title":"Subclinical antibody-mediated rejection after kidney transplantation: treatment outcomes.","volume":"103","author":"Parajuli","year":"2019","journal-title":"Transplantation"},{"key":"R51-20250604","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/ajt.12982","article-title":"Quantifying renal allograft loss following early antibody-mediated rejection.","volume":"15","author":"Orandi","year":"2015","journal-title":"Am J Transplant"},{"key":"R52-20250604","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/tri.13970","article-title":"Diagnostic value of donor-derived cell-free DNA to predict antibody-mediated rejection in donor-specific antibody-positive renal allograft recipients.","volume":"34","author":"Mayer","year":"2021","journal-title":"Transpl Int"},{"key":"R53-20250604","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1681\/ASN.2014040399","article-title":"Subclinical rejection phenotypes at 1 year post-transplant and outcome of kidney allografts.","volume":"26","author":"Loupy","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"R54-20250604","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1097\/TP.0000000000002567","article-title":"Early diagnosis and treatment of subclinical amr is vital for improving clinical outcomes.","volume":"103","author":"Chittka","year":"2019","journal-title":"Transplantation"},{"key":"R55-20250604","first-page":"110","article-title":"The pathology of renal transplants.","volume":"51","author":"Vazquez Martul","year":"2018","journal-title":"Rev Esp Patol"},{"key":"R56-20250604","doi-asserted-by":"crossref","first-page":"e1360","DOI":"10.1097\/TXD.0000000000001360","article-title":"Chronic active antibody-mediated rejection in kidney transplant recipients: treatment response rates and value of early surveillance biopsies.","volume":"8","author":"Aziz","year":"2022","journal-title":"Transplant Direct"},{"key":"R57-20250604","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1681\/ASN.2021091191","article-title":"The Trifecta study: comparing plasma levels of donor-derived cell-free DNA with the molecular phenotype of kidney transplant biopsies.","volume":"33","author":"Halloran","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"R58-20250604","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1111\/ajt.14329","article-title":"Real time central assessment of kidney transplant indication biopsies by microarrays: the INTERCOMEX study.","volume":"17","author":"Halloran","year":"2017","journal-title":"Am J Transplant"},{"key":"R59-20250604","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.kint.2021.11.034","article-title":"Clinical outcomes from the assessing donor-derived cell-free DNA monitoring insights of kidney allografts with longitudinal surveillance (ADMIRAL) study.","volume":"101","author":"Bu","year":"2022","journal-title":"Kidney Int"},{"key":"R60-20250604","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3390\/jcm10020193","article-title":"Donor-derived cell-free DNA in kidney transplantation as a potential rejection biomarker: a systematic literature review.","volume":"10","author":"Martuszewski","year":"2021","journal-title":"J Clin Med"},{"key":"R61-20250604","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","article-title":"Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence.","volume":"12","author":"Sellares","year":"2012","journal-title":"Am J Transplant"},{"key":"R62-20250604","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1681\/ASN.2014060588","article-title":"Disappearance of T cell-mediated rejection despite continued antibody-mediated rejection in late kidney transplant recipients.","volume":"26","author":"Halloran","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"R63-20250604","doi-asserted-by":"crossref","first-page":"842419","DOI":"10.3389\/fmed.2022.842419","article-title":"Causes of kidney graft failure in a cohort of recipients with a very long-time follow-up after transplantation.","volume":"9","author":"Betjes","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R64-20250604","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/FTD.0000000000001023","article-title":"Donor-derived cell-free DNA for personalized immunosuppression in renal transplantation.","volume":"45","author":"Oellerich","year":"2023","journal-title":"Ther Drug Monit"},{"key":"R65-20250604","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/TP.0000000000004396","article-title":"Relating molecular T cell-mediated rejection activity in kidney transplant biopsies to time and to histologic tubulitis and atrophy-fibrosis.","volume":"107","author":"Madill-Thomsen","year":"2023","journal-title":"Transplantation"},{"issue":"Suppl 2","key":"R66-20250604","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/nep.12450","article-title":"Microvascular inflammation in early protocol biopsies of renal allografts in cases of chronic active antibody-mediated rejection.","volume":"20","author":"Tsuji","year":"2015","journal-title":"Nephrology (Carlton)"},{"key":"R67-20250604","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/ki.2015.276","article-title":"Clinical and molecular significance of microvascular inflammation in transplant kidney biopsies.","volume":"89","author":"Gupta","year":"2016","journal-title":"Kidney Int"},{"key":"R68-20250604","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/ki.2013.300","article-title":"Antibody-mediated rejection, T cell-mediated rejection, and the injury-repair response: new insights from the Genome Canada studies of kidney transplant biopsies.","volume":"85","author":"Halloran","year":"2014","journal-title":"Kidney Int"},{"key":"R69-20250604","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/cpt.2256","article-title":"When are treatment blinding and treatment standardization necessary in real-world clinical trials?","volume":"111","author":"Watanabe","year":"2022","journal-title":"Clin Pharmacol Ther"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T14:10:51Z","timestamp":1749046251000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,20]]},"references-count":68,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000005007","relation":{},"ISSN":["0041-1337","1534-6080"],"issn-type":[{"value":"0041-1337","type":"print"},{"value":"1534-6080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,20]]}}}